Real-World Evidence from Ongoing Oncology Clinical Trials

Why Real‑World Evidence Matters in Oncology

Real‑world data (RWD) are health status and care delivery information routinely captured from electronic health records, registries, claims and patient‑reported outcomes. When analyzed, RWD generate real‑world evidence (RWE)—clinical insights on how oncology therapies perform in everyday practice. Unlike randomized controlled trials (RCTs), which enroll narrowly selected patients under strict eligibility criteria, RWE reflects heterogeneous populations, including older adults, comorbidities and rare molecular sub‑groups. This broader representativeness can reveal effectiveness, safety and cost‑effectiveness that RCTs may miss. The FDA’s Oncology Center of Excellence Real‑World Evidence Program, mandated by the 21st Century Cures Act, now accepts RWE for label expansions, post‑marketing surveillance and even external control arms. Consequently, clinicians can make more informed, patient‑centered decisions while regulators gain evidence of therapeutic value.

Understanding Real‑World Data Sources and Types

Real‑world data (RWD) are information collected from patients during health‑care delivery. Main sources include electronic health records (EHRs) with diagnoses, procedures, labs, medication orders and notes; administrative claims and billing data documenting services, costs and prescription fills; patient‑reported outcomes (PROs) and wearable‑generated data reflecting symptoms, functioning and adherence; and disease‑specific registries that provide longitudinal detail on therapies and outcomes for conditions such as pancreatic cancer.

Randomized controlled trials (RCTs) rely on internal validity through randomization, blinding and strict eligibility, yielding robust efficacy and safety signals but often enrolling a population. Real‑world evidence (RWE) derives from RWD, offering validity by showing how treatments perform across heterogeneous groups, settings, and over follow‑up, though it is more vulnerable to bias and confounding.

In oncology, RWD enable analysis of treatment patterns, safety signals and survival trends that trials cannot capture, especially for rare molecular subpopulations or patients with comorbidities. For Hirschfeld Oncology, integrating RWD into plans helps identify gaps, refine sequencing, and support advocacy while acknowledging the need for careful controls.

Regulatory Landscape and Guidance

The U.S. Food and Drug Administration defines real‑world evidence (RWE) as clinical information about a medical product’s use, benefits and and risks that is derived from analyses of real‑world data (RWD) such as electronic health records, claims and registries. Since the 21st Century Cures Act, the FDA has created a formal framework allowing RWE to support new drug indications, post‑approval studies and even medical‑device reviews, with recent guidance permitting de‑identified, large‑scale datasets. The Oncology Center of Excellence (OCE) Real‑World Evidence Program aligns with this mandate, advancing scientific collaboration, strategic partnerships and training to build knowledge, develop novel endpoints and create external control comparators. OCE’s active collaborations with organizations like Flatiron Health, Aetion and Syapse focus on treatment‑pattern analyses, safety monitoring and COVID‑19 impact. The Office of Prescription Drug Promotion (OPDP) now scrutinizes promotional claims that rely on RWE, requiring rigorous validation to meet “adequate and well‑controlled” standards. For oncology centers such as Hirschfeld Oncology, leveraging high‑quality RWE can accelerate access to innovative pancreatic‑cancer therapies while ensuring regulatory confidence and transparent patient communication.

Methodological Strengths, Challenges, and Standards

Real‑world database (RWD) studies have become a cornerstone of oncology research, offering insights into treatment patterns, outcomes, and health‑care delivery that cannot be captured in traditional trials. However, the diversity of data sources—claims, electronic health records, registries, and patient‑generated information—introduces heterogeneity, bias, and gaps in transparency that can compromise validity.

Selection bias and confounding remain the chief methodological challenges because treatment choices in routine care are influenced by patient characteristics. Without randomization, observed differences may reflect underlying risk factors rather than true drug effects.

Statistical mitigation such as propensity‑score matching, inverse‑probability weighting, and multivariable adjustment can reduce but not eliminate bias, making careful cohort definition and sensitivity analyses essential.

Standardization initiatives—including the FDA Oncology Real‑World Evidence Program, ASCO fitness‑for‑purpose guidelines, and collaborative pilots by Flatiron, Aetion, and COTA—are establishing common data models, endpoint definitions, and reporting standards to improve reproducibility and regulatory confidence.

Why is RWE so popular? Regulators now accept RWE for approvals and post‑marketing surveillance, AI and machine‑learning turn heterogeneous data into actionable insights, and patient‑reported outcomes capture real‑life experiences missed by trials.

Real‑world evidence oncology refers to clinical insights derived from RWD such as EHRs, registries, claims, and PROs. The FDA’s Oncology Center of Excellence uses RWE to complement RCTs, evaluating safety, effectiveness, and comparative performance in everyday practice.

Real world evidence clinical trial integration lets Hirschfeld Oncology combine trial rigor with real‑world generalizability, refining treatment algorithms, identifying responsive sub‑groups, and supporting regulatory submissions with robust, patient‑centric data.

Real‑World Evidence in Pancreatic Cancer: Clinical Impact

Real‑world data studies Real‑world data (RWD) studies analyze information collected outside traditional trials—electronic health records, claims, Patient‑reported outcome tools and disease registries—to assess how pancreatic cancer therapies perform in everyday practice. By mining these sources, researchers evaluate safety, effectiveness, and care patterns across diverse patients. The FDA increasingly accepts RWE to support regulatory decisions, enabling Hirschfeld Oncology to refine protocols, identify care gaps, and personalize regimens based on actual outcomes.

Real‑world evidence examples EHR datasets track treatment sequences, laboratory trends, and survival for patients receiving standard gemcitabine‑nab‑paclitaxel combined with novel agents. Medicare and private‑insurer claims reveal utilization, hospitalizations, and costs of different therapeutic lines. Patient‑reported outcome tools capture symptom burden and quality‑of‑life, while disease‑specific registries (e.g., National Pancreatic Cancer Registry) link molecular data to long‑term survival. Post‑marketing device registries provide safety data for innovative delivery systems.

Real world evidence in pharmacovigilance RWE detects rare or long‑term toxicities not seen in trials, supports continuous risk‑benefit assessment, and informs labeling updates. FDA guidance encourages its use for post‑marketing commitments, allowing oncology teams to monitor drug safety in real time and improve patient outcomes.

Real‑world data and clinical experience from over 100,000 multi‑cancer early detection tests In a cohort of 111,080 adults, the Galleri® MCED test identified a cancer signal in 0.91 % of participants. Follow‑up confirmed invasive cancer in 258 of 459 positives, spanning 32 tumor types, with correct anatomical localization in 87 % and a median diagnostic interval of 39.5 days, illustrating the potential of large‑scale RWE to guide timely clinical management.

Key Statistics and Survival Insights

Cancer treatment and survivorship statistics 2026 In 2026 an estimated 2.1 million Americans will be diagnosed with cancer and about 626,000 will die, averaging roughly 5,800 new cases and 1,720 deaths each day. The overall five‑year relative survival for cancers diagnosed during 2015‑2021 has reached a historic 70 %, up from 49 % in the mid‑1970s. Despite this progress, disparities persist across geography and race.

Cancer survivor statistics As of Jan 1 2025, ~18.6 million Americans—about one in 18—are living as cancer survivors. By 2035 this will exceed 22 million. Seventy percent have survived at least five years; 49 % ten years or more.

Cancer survival rates by age Five‑year survival declines with age: lung‑cancer survival is ~42 % at 20‑44 y, 30 % at 45‑54 y, 28 % at 55‑64 y, 22 % at 65‑74 y, and 16 % at ≥75 y. Adolescents/young adults enjoy ~86 % survival.

5‑year survival rate by cancer type Thyroid (98.4 %) and prostate (97.5 %) have the highest five‑year survival; pancreatic cancer is lowest at 12.8 %.

What are the top 3 most curable cancers? Prostate, thyroid, and testicular cancers each exceed 95 % five‑year survival when detected early.

What are the chances of surviving cancer stage 4? Stage 4 five‑year survival ranges from <5 % (pancreatic, lung) to 20‑30 % (selected breast, prostate).

Stage 4 cancer survivors stories Patients with metastatic disease have achieved long‑term remission through targeted therapies, clinical‑trial enrollment, and multidisciplinary care, exemplifying the impact of personalized treatment at Hirschfeld Oncology.

Future Directions: Hybrid Trials, AI, and Patient‑Centric RWE

Hybrid trial designs that blend randomized arms with external control cohorts from electronic health records, registries, and claims expand oncology research. Real‑world evidence (RWE) augments RCTs, allowing assessment of effectiveness in broader populations while maintaining statistical rigor.

Artificial intelligence and machine‑learning tools streamline curation of unstructured EHR notes, harmonize variables, and create propensity‑score matched cohorts, reducing bias and speeding insight.

Patient‑reported outcomes captured via mobile apps or wearables feed shared decision‑making, balancing efficacy with quality‑of‑life.

Real‑world evidence PhD – a doctoral program training scientists in epidemiology, biostatistics, health economics and data‑science to turn RWD into actionable oncology insights.

Real‑world evidence – clinical insight from health data to assess safety, effectiveness, and long‑term outcomes across diverse patients.

Real‑world evidence examples – EHR‑based treatment tracking, claims‑derived utilization, PRO surveys, disease registries, and post‑marketing device data.

Real‑world evidence in pharmacovigilance – detects rare adverse events and supports risk‑benefit assessment.

Real‑world evidence clinical trial – integrates RWE with RCT data to refine algorithms, identify sub‑groups, and support regulatory decisions.

A New Era of Evidence‑Driven Oncology Care

At Hirschfeld Oncology, we are weaving real‑world evidence (RWE) into daily clinical decision‑making to ensure every patient benefits from the latest scientific insights. By linking electronic health records, registry data, and patient‑reported outcomes, we evaluate treatment effectiveness across the diverse, often older, pancreatic cancer population that traditional trials exclude. This integration supports our commitment to personalized, compassionate care, allowing us to tailor chemotherapy, targeted agents, and immunotherapies to individual tumor biology and comorbidities. Looking ahead, ongoing hybrid trials and expanded RWE collaborations promise faster validation of innovative regimens, ultimately improving survival and quality of life for our patients.